- The FDA accepts under Priority Review Shire plc's (NASDAQ:SHPG) supplemental Biologics License Application (sBLA) seeking approval to use CINRYZE (C1 esterase inhibitor [human]) to treat children as young as six years old with hereditary angioedema (HAE). The agency's action date is June 20.
- CINRYZE is currently approved in the U.S. for adolescent and adult HAE patients.